Superworth

Organon OGN

Drug Manufacturers - General, Healthcare
$13.82
−0.14%
Market cap
$3.6B
PE
18.2×
5y median 6.0×
Forward PE
n/m
not a meaningful number
Price to sales
0.6×
EV/EBIT
9.5×
Revenue, 12 months
$6.1B
−3% on a year ago
Net margin
3.5%
Free cash flow yield
18.6%

Organon trades at 18.2× trailing earnings, pricier than 99% of the last ten years. Revenue was $6.1B over the last twelve months, down 3% on a year earlier with a 3% net margin.

Charts

Financials

Income statement for OGN, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$1.6B+8%$1.6B+6%$1.6B−0%$1.6B+4%$1.6B−0%$1.5B−7%$1.6B−1%$1.6B+1%$1.5B−5%$1.5B−4%$1.6B−2%$1.6B−2%
Cost of revenue$683M+15%$665M+15%$668M+4%$659M+8%$696M+2%$672M+1%$720M+8%$745M+13%$766M+10%$677M+1%$711M−1%$705M−5%
Gross profit$915M+3%$957M−0%$939M−3%$923M+2%$896M−2%$841M−12%$874M−7%$857M−7%$741M−17%$783M−7%$847M−3%$869M+1%
R&D$134M−6%$112M−13%$116M−9%$111M−19%$130M−3%$96M−14%$95M−18%$84M−24%$91M−30%$93M−3%$90M−5%$83M−1%
SG&A$469M−0%$431M−1%$437M−3%$422M−22%$470M+0%$420M−3%$453M+4%$415M−2%$433M−8%$424M+1%$434M−4%$421M+1%
$254M−3%$376M−2%$371M−5%$339M+46%$288M+13%$233M−38%$324M−13%$358M+6%−$91M$235M+1%$322M−1%$365M+2%
Interest expense$129M+8%$131M−1%$131M−1%$126M−6%$132M+2%$124M−5%$131M+0%$128M+2%$121M−8%$111M−11%$108M−18%$106M−17%
Pre-tax income$104M−6%$236M+0%$235M−8%$207M+159%$129M+24%$101M−57%$229M−3%$243M+17%−$148M$213M+111%$183M−20%$255M+5%
−$442M$35M−40%$40M+233%−$152M$20M$14M−60%$84M+110%$83M$57M+185%$67M+379%$75M−11%$91M+10%
Net income$546M+406%$201M+14%$195M−19%$359M+519%$109M−80%$87M−57%$145M−26%$160M−55%−$205M$146M+68%$108M−26%$164M+3%
$2.13+407%$0.78+13%$0.75−21%$1.38+500%$0.42−80%$0.33−58%$0.56−25%$0.61−56%−$0.79$0.55+67%$0.40−29%$0.60−2%
256.6M+1%258.4M+1%258.6M+1%259.8M+1%259.9M+1%261M+1%260.2M+1%260.7M+0%260.2M+0%262.9M+1%270.4M+4%272.4M+5%

Gross profit: 17 periods, Q1 FY20 to Q1 FY24: not printed by the filing, worked out from its own lines.

Operating income: 27 periods, Q1 FY20 to Q3 FY26: not printed by the filing, worked out from its own lines.

Interest expense: Q1 FY20: 6 months less the 3 months printed beside them.

EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 5 periods, Q4 FY20 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Organon's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
OGNOrganon$3.6B18.2×6.0×0.6×−3%3.5%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
ARQTArcutis Biotherapeutics$3.9B142×117×8.5×+76%6.1%
INDVIndivior Pharmaceuticals$4.3B10.2×19.9×3.1×+16%32.8%
NRIXNurix Therapeutics$2.8B11.1×11.0×4.0×n/m42.0%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
LGNDLigand Pharmaceuticals$6.1B32.7×37.6×21.1×+55%67.9%
AMRXAmneal Pharmaceuticals$6.5B41.7×51.4×2.1×+9%5.0%
KNSAKiniksa Pharmaceuticals International$7.1B93.6×87.6×8.4×+59%9.6%
ALKSAlkermes plc.$7.5B118×16.0×4.5×+11%4.0%
Peer median$4.1B31.4×28.8×4.3×+20%17.2%

More on Organon

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .